316 related articles for article (PubMed ID: 21896924)
1. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.
Nightingale G
Ann Pharmacother; 2011 Oct; 45(10):1248-55. PubMed ID: 21896924
[TBL] [Abstract][Full Text] [Related]
2. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Lemery SJ; Zhang J; Rothmann MD; Yang J; Earp J; Zhao H; McDougal A; Pilaro A; Chiang R; Gootenberg JE; Keegan P; Pazdur R
Clin Cancer Res; 2010 Sep; 16(17):4331-8. PubMed ID: 20601446
[TBL] [Abstract][Full Text] [Related]
3. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
Wierda WG; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJ; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Davis R; Losic N; Wilms J; Russell CA; Osterborg A;
J Clin Oncol; 2010 Apr; 28(10):1749-55. PubMed ID: 20194866
[TBL] [Abstract][Full Text] [Related]
4. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
Reagan JL; Castillo JJ
Expert Rev Anticancer Ther; 2011 Feb; 11(2):151-60. PubMed ID: 21342032
[TBL] [Abstract][Full Text] [Related]
5. Ofatumumab for treating chronic lymphocytic leukemia: a safety profile.
Korycka-Wołowiec A; Wołowiec D; Robak T
Expert Opin Drug Saf; 2015; 14(12):1945-59. PubMed ID: 26566719
[TBL] [Abstract][Full Text] [Related]
6. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.
Bauer K; Rancea M; Roloff V; Elter T; Hallek M; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008079. PubMed ID: 23152253
[TBL] [Abstract][Full Text] [Related]
7. Ofatumumab for the treatment of chronic lymphocytic leukemia.
Grosicki S
Expert Rev Hematol; 2015 Jun; 8(3):265-72. PubMed ID: 25882470
[TBL] [Abstract][Full Text] [Related]
8. Ofatumumab in the treatment of chronic lymphocytic leukemia.
Tsimberidou AM
Drugs Today (Barc); 2010 Jul; 46(7):451-61. PubMed ID: 20683500
[TBL] [Abstract][Full Text] [Related]
9. Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK.
Hoyle M; Crathorne L; Garside R; Hyde C
Health Technol Assess; 2011 May; 15 Suppl 1():61-7. PubMed ID: 21609654
[TBL] [Abstract][Full Text] [Related]
10. Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.
Reagan JL; Castillo JJ
Future Oncol; 2014 May; 10(7):1147-55. PubMed ID: 24947256
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Ogura M; Hatake K; Tobinai K; Uchida T; Suzuki T; Terui Y; Yokoyama M; Maruyama D; Mori M; Jewell RC; Katsura K; Hotta T
Jpn J Clin Oncol; 2013 May; 43(5):466-75. PubMed ID: 23456745
[TBL] [Abstract][Full Text] [Related]
12. The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use.
Gravanis I; Ersbøll J; Skovlund E; Abadie E; Marty M; Pignatti F
Oncologist; 2010; 15(12):1335-43. PubMed ID: 21156732
[TBL] [Abstract][Full Text] [Related]
13. Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.
Barth MJ; Czuczman MS
Future Oncol; 2013 Dec; 9(12):1829-39. PubMed ID: 24295413
[TBL] [Abstract][Full Text] [Related]
14. Ofatumumab, a human anti-CD20 monoclonal antibody.
Osterborg A
Expert Opin Biol Ther; 2010 Mar; 10(3):439-49. PubMed ID: 20109133
[TBL] [Abstract][Full Text] [Related]
15. Ofatumumab.
Sanford M; McCormack PL
Drugs; 2010 May; 70(8):1013-9. PubMed ID: 20481657
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis.
Struemper H; Sale M; Patel BR; Østergaard M; Österborg A; Wierda WG; Hagenbeek A; Coiffier B; Jewell RC
J Clin Pharmacol; 2014 Jul; 54(7):818-27. PubMed ID: 24443277
[TBL] [Abstract][Full Text] [Related]
17. Ofatumumab in refractory chronic lymphocytic leukemia: experience through the French early access program.
Dupuis J; Brice P; François S; Ysebaert L; de Guibert S; Levy V; Leprêtre S; Choquet S; Dilhuydy MS; Fornecker L; Morel V; Tempescul A
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):e43-6. PubMed ID: 25193089
[TBL] [Abstract][Full Text] [Related]
18. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
Cheson BD
J Clin Oncol; 2010 Jul; 28(21):3525-30. PubMed ID: 20458041
[TBL] [Abstract][Full Text] [Related]
19. Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia.
O'Brien S; Osterborg A
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):361-8. PubMed ID: 21030349
[TBL] [Abstract][Full Text] [Related]
20. Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Bello C; Veliz M; Pinilla-Ibarz J
Expert Rev Clin Immunol; 2011 May; 7(3):295-300. PubMed ID: 21595596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
